Tissue Repair Ltd (AU:TRP)
ASX:TRP
Want to see AU:TRP full AI Analyst Report?
TRP Stock Chart & Stats
AU$0.38
AU$0.02(5.56%)
At close: 4:00 PM EST
AU$0.38
AU$0.02(5.56%)
Day’s Range― - ―
52-Week RangeAU$0.11 - AU$0.48
Previous CloseN/A
Volume13.59K
Average Volume (3M)93.72K
Market Cap
AU$7.56M
Enterprise Value-AU$736.36K
Total Cash (Recent Filing)AU$12.32M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding60,464,844
10 Day Avg. Volume171,402
30 Day Avg. Volume93,720
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)0.80
Price to Sales (P/S)4.25
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue AccelerationA large revenue increase in 2025 indicates meaningful traction for products or services and validates market demand. Sustained top-line growth can support fixed-cost absorption and scaling, providing a structural path toward improved operating leverage and eventual profit conversion if maintained.
Very High Gross MarginsPersistently high gross margins create durable upside to operating leverage as revenue scales, enabling the company to cover fixed R&D and SG&A without proportionally increasing costs. This margin profile supports long-term profitability once operating expenses stabilize or decline as a percent of sales.
Debt-free Balance SheetHaving no reported debt materially reduces financial risk and interest burden, giving management flexibility to fund R&D, commercialization, or strategic initiatives via equity or grants. A debt-free structure improves resilience to revenue volatility and lowers bankruptcy risk over the medium term.
Bears Say
Negative And Worsening Cash FlowConsistent negative operating and free cash flow, and a deterioration in 2025, signal rising cash burn that will require external financing to sustain operations. This structural cash shortfall increases dilution risk and constrains the company's ability to invest opportunistically or scale without securing new capital.
Deep, Persistent Operating LossesVery negative margins and ongoing operating losses indicate the business is still in heavy investment mode with limited near-term earnings visibility. Prolonged losses reduce retained capital, weaken ROE, and make the firm dependent on external funding, raising execution risk on the path to profitability.
Material Equity Erosion / Funding RiskA substantial decline in shareholders' equity over several years reflects cumulative losses or dilution and shrinks the company's capital buffer. This undermines financial flexibility, increases the likelihood of further dilutive raises, and can constrain strategic choices or lead to tighter covenant/financing terms.
Tissue Repair Ltd News
TRP FAQ
What was Tissue Repair Ltd’s price range in the past 12 months?
Tissue Repair Ltd lowest share price was AU$0.11 and its highest was AU$0.48 in the past 12 months.
What is Tissue Repair Ltd’s market cap?
Tissue Repair Ltd’s market cap is AU$7.56M.
When is Tissue Repair Ltd’s upcoming earnings report date?
Tissue Repair Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 101 days.
How were Tissue Repair Ltd’s earnings last quarter?
Tissue Repair Ltd released its earnings results on Feb 27, 2026. The company reported -AU$0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.036.
Is Tissue Repair Ltd overvalued?
According to Wall Street analysts Tissue Repair Ltd’s price is currently Overvalued.
Does Tissue Repair Ltd pay dividends?
Tissue Repair Ltd does not currently pay dividends.
What is Tissue Repair Ltd’s EPS estimate?
Tissue Repair Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tissue Repair Ltd have?
Tissue Repair Ltd has 60,464,844 shares outstanding.
What happened to Tissue Repair Ltd’s price movement after its last earnings report?
Tissue Repair Ltd reported an EPS of -AU$0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Tissue Repair Ltd?
Currently, no hedge funds are holding shares in AU:TRP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tissue Repair Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.23%
12-Months-Change
Fundamentals
Return on Equity
-29.91%
Trailing 12-Months
Asset Growth
-25.56%
Trailing 12-Months
Company Description
Tissue Repair Ltd
Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987 and other dressing/matrices, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Bio-Gene Technology Ltd.
―
Options Prices
Currently, No data available
---